Van bölgesinde özofagus kanserlerinde yaşam süresine bazı prognostik faktörlerin ve tedavi modalitelerinin etkisinin retrospesifik analizi
Retrospective analysis of the effects of same prognostic factors and the therapetic modalities on survival of the esophagus cancer patients in Van region
Yazar: GÖKTÜRK KILINÇ
Danışman: DOÇ. DR. MAHMUT İLHAN
Yüzüncü Yıl Üniversitesi / Tıp Fakültesi / İç Hastalıkları Ana Bilim Dalı
Derece: Tıpta Uzmanlık, 2007
Konu: Onkoloji = Oncology

Özet:
Esophageal cancers are more prevalent in some regions of the world which are associated with a high mortality. They are among most common malignancies observed in our region. İn this study, we aimed to describe prognostic factors which may influence the survival of esophageal cancer patients. 356 esophagus cancer patients that recorded in medical oncology policlinic of school of medicine in University hospital of Yuzuncu Yil University were retrospectively evaluated. The data of 292 patients whose survival results could be obtained were evaluated. The effect of different treatment modalities and clinicopathologic parameters on the survival was searched. The median age is 56, 52.8% of patients were women and 47.2% men. The 74.7% of patients were squamous cell carcinoma and the remaining 25.3% adenocarcinoma. 32.5% of patients were localized, 39.7% locally-advanced and 27.3% were found to be metastatic at the time of diagnosis. Of patients, 4.8% proximal, 46.1% middle and 48% distal part of esophagus were involved. The 46 patients were underwent surgery alone, 96 only chemotherapy, 51 primary curative chemoradiotherapy, 35 surgery plus chemotherapy and 20 patients were underwent surgery plus chemoradiotherapy. The median survival was 13 months and 1 and 3 year survival rates were 55% and 9% respectively. When we look at local and locally-advanced stage, median survival was 15 months, 1 and 3 year survival rates were 62% and 12% respectively. On contrary, median survival was 8 months, 1 and 3 year survival rates were 36% and 0% respectively. In univariate analysis, the stage, tumor length, the therapy given, the applied surgery type and the number of chemotherapy cycles were found to be related to survival (p<0,05). There is no effect of histologic type, age, gender and the involvement area on the survival. There are no survival difference between only chemotherapy, only surgery and only chemoradiotherapy but surgery plus chemotherapy or chemoradiotherapy is superior than only surgery. In patients with metastatic stage palliative chemotherapy and chemoradiotherapy were related to survival. Keywords: esophagus cancer, survival

Abstract:
Esophageal cancers are more prevalent in some regions of the world which are associated with a high mortality. They are among most common malignancies observed in our region. İn this study, we aimed to describe prognostic factors which may influence the survival of esophageal cancer patients. 356 esophagus cancer patients that recorded in medical oncology policlinic of school of medicine in University hospital of Yuzuncu Yil University were retrospectively evaluated. The data of 292 patients whose survival results could be obtained were evaluated. The effect of different treatment modalities and clinicopathologic parameters on the survival was searched. The median age is 56, 52.8% of patients were women and 47.2% men. The 74.7% of patients were squamous cell carcinoma and the remaining 25.3% adenocarcinoma. 32.5% of patients were localized, 39.7% locally-advanced and 27.3% were found to be metastatic at the time of diagnosis. Of patients, 4.8% proximal, 46.1% middle and 48% distal part of esophagus were involved. The 46 patients were underwent surgery alone, 96 only chemotherapy, 51 primary curative chemoradiotherapy, 35 surgery plus chemotherapy and 20 patients were underwent surgery plus chemoradiotherapy. The median survival was 13 months and 1 and 3 year survival rates were 55% and 9% respectively. When we look at local and locally-advanced stage, median survival was 15 months, 1 and 3 year survival rates were 62% and 12% respectively. On contrary, median survival was 8 months, 1 and 3 year survival rates were 36% and 0% respectively. In univariate analysis, the stage, tumor length, the therapy given, the applied surgery type and the number of chemotherapy cycles were found to be related to survival (p<0,05). There is no effect of histologic type, age, gender and the involvement area on the survival. There are no survival difference between only chemotherapy, only surgery and only chemoradiotherapy but surgery plus chemotherapy or chemoradiotherapy is superior than only surgery. In patients with metastatic stage palliative chemotherapy and chemoradiotherapy were related to survival. Keywords: esophagus cancer, survival